Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia

Therapeutic Drug Monitoring

Volumn 20, Issue 6, 1998, Pages 628-630

  Facciolà, Gabriella ^a   Avenoso, Angela ^a   Spina, Edoardo ^a,b   Perucca, Emilio ^c  

^a UNIVERSITY OF MESSINA   (Italy)

^b USL 5   (Italy)

^c NONE

Author keywords

Clozapine; Clozapine N oxide; Drug interaction; Enzyme induction; Norclozapine; Phenobarbital

Indexed keywords

CLOZAPINE; CLOZAPINE N OXIDE; CYTOCHROME P450; DRUG METABOLITE; NORCLOZAPINE; PHENOBARBITAL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG OXIDATION; ENZYME INDUCTION; EPILEPSY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; CLOZAPINE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INDUCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOBARBITAL; SCHIZOPHRENIA;

EID: 0031725427     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199812000-00008     Document Type: Article

References (17)

1. Baldessarini RJ, Frankenburg FR. Clozapine, a novel antipsychotic agent. New Engl J Med 1991;324:746-54.
2. Jann MW, Grimsley SR, Gray EC, et al. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993;24: 161-76.
3. Haring C, Fleishacker WW, Schett P, et al. Influence of patient-related variables on clozapine plasma concentrations. Am J Psychiatry 1990;147:1471-5.
4. Edge SC, Markovitz JS, DeVane CL. Clozapine drug-drug interactions: A review of the literature. Hum Psychopharmacol 1997; 12:5-20.
5. Freeman DJ, Oyewumi LK. Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin Pharmacokinet 1997;32:93-100.
6. Jerling M, Lindstrom L, Bondesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-74.
7. Raitasuo V, Lehtovaara R, Huttonen MO. Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. Psychopharmacology 1994;116:115-6.
8. Tiihonen M, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry 1995;28;26-8.
9. Miller D. Effect of phenytoin on plasma clozapine concentration in two patients. J Clin Psychiatr 1991;52:23-5.
10. Avenoso A, Facciolà G, Campo GM, et al. Determination of clozapine, N-desmethylclozapine, and clozapine N-oxide in human plasma by reverse phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl 1998;714:299-308.
11. Eiermann B, Engel G, Johansson I, et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997;44:439-46.
12. Pirmohamed M, Williams D. Madden S, et al. Metabolism and biactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995;272:984-90.
13. Bertilsson L, Carrillo JA, Dahl M-L, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994;38:471-3.
14. Brosen K, Skielbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P450 1A2. Biochem Pharmacol 1993;45:1211-4.
15. Hiemke C, Weigmann H, Hartter S, et al. Elevated plasma levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994;14:279-81.
16. Perucca E, Richens A. Biotransformation. In Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs. 4th ed. New York: Raven, 1995:31-50.
17. Sesardic D, Boobis AR, Edwards RJ, A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 1988;26:363-72.